1470 related articles for article (PubMed ID: 18249467)
1. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
[TBL] [Abstract][Full Text] [Related]
3. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
4. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance.
Nambiar S; Mirmohammadsadegh A; Hassan M; Mota R; Marini A; Alaoui A; Tannapfel A; Hegemann JH; Hengge UR
Carcinogenesis; 2007 Dec; 28(12):2501-10. PubMed ID: 17768177
[TBL] [Abstract][Full Text] [Related]
5. Expression of thyrotropin-releasing hormone by human melanoma and nevi.
Ellerhorst JA; Naderi AA; Johnson MK; Pelletier P; Prieto VG; Diwan AH; Johnson MM; Gunn DC; Yekell S; Grimm EA
Clin Cancer Res; 2004 Aug; 10(16):5531-6. PubMed ID: 15328193
[TBL] [Abstract][Full Text] [Related]
6. Minichromosome maintenance proteins are useful adjuncts to differentiate between benign and malignant melanocytic skin lesions.
Gambichler T; Shtern M; Rotterdam S; Bechara FG; Stücker M; Altmeyer P; Kreuter A
J Am Acad Dermatol; 2009 May; 60(5):808-13. PubMed ID: 19389522
[TBL] [Abstract][Full Text] [Related]
7. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.
Touab M; Arumi-Uría M; Barranco C; Bassols A
Am J Clin Pathol; 2003 Apr; 119(4):587-93. PubMed ID: 12710131
[TBL] [Abstract][Full Text] [Related]
8. Nucleolin protein expression in cutaneous melanocytic lesions.
Mourmouras V; Cevenini G; Cosci E; Epistolato MC; Biagioli M; Barbagli L; Luzi P; Mannucci S; Miracco C
J Cutan Pathol; 2009 Jun; 36(6):637-46. PubMed ID: 19515042
[TBL] [Abstract][Full Text] [Related]
9. MSG-1 expression in benign and malignant melanocytic lesions of cutaneous and mucosal epithelium.
Sedghizadeh PP; Williams JD; Allen CM; Prasad ML
Med Sci Monit; 2005 Jul; 11(7):BR189-94. PubMed ID: 15990678
[TBL] [Abstract][Full Text] [Related]
10. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
11. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma.
Giehl KA; Nägele U; Volkenandt M; Berking C
J Cutan Pathol; 2007 Jan; 34(1):7-14. PubMed ID: 17214848
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
[TBL] [Abstract][Full Text] [Related]
13. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.
Gambichler T; Rotterdam S; Radkowski K; Altmeyer P; Kreuter A
Am J Clin Pathol; 2009 May; 131(5):710-4. PubMed ID: 19369632
[TBL] [Abstract][Full Text] [Related]
16. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi.
Sand M; Gambichler T; Sand D; Altmeyer P; Stuecker M; Bechara FG
Eur J Dermatol; 2011; 21(1):18-21. PubMed ID: 21262599
[TBL] [Abstract][Full Text] [Related]
18. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
[TBL] [Abstract][Full Text] [Related]
19. Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms.
Cohn ML; Goncharuk VN; Diwan AH; Zhang PS; Shen SS; Prieto VG
J Cutan Pathol; 2005 Sep; 32(8):533-6. PubMed ID: 16115050
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of telomerase activity in cutaneous melanocytic proliferations.
Miracco C; Pacenti L; Santopietro R; Laurini L; Biagioli M; Luzi P
Hum Pathol; 2000 Sep; 31(9):1018-21. PubMed ID: 11014565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]